Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
1.62
Dollar change
+0.02
Percentage change
1.25
%
IndexRUT P/E- EPS (ttm)-0.33 Insider Own37.34% Shs Outstand127.67M Perf Week-4.71%
Market Cap222.90M Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float86.21M Perf Month-26.03%
Income-42.49M PEG- EPS next Q-0.11 Inst Own38.83% Short Float1.88% Perf Quarter-8.47%
Sales0.00M P/S- EPS this Y-46.75% Inst Trans2.93% Short Ratio4.13 Perf Half Y-18.18%
Book/sh1.16 P/B1.39 EPS next Y-3.83% ROA-23.84% Short Interest1.62M Perf Year-49.06%
Cash/sh1.11 P/C1.46 EPS next 5Y- ROE-25.74% 52W Range1.15 - 3.62 Perf YTD3.85%
Dividend Est.- P/FCF- EPS past 5Y12.88% ROI-28.51% 52W High-55.25% Beta0.63
Dividend TTM- Quick Ratio19.73 Sales past 5Y0.00% Gross Margin- 52W Low40.87% ATR (14)0.18
Dividend Ex-Date- Current Ratio19.73 EPS Y/Y TTM10.54% Oper. Margin0.00% RSI (14)38.54 Volatility12.74% 10.53%
Employees32 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.43 Target Price9.17
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-5.10% Payout- Rel Volume1.52 Prev Close1.60
Sales Surprise- EPS Surprise-16.65% Sales Q/Q- EarningsMar 21 BMO Avg Volume393.30K Price1.62
SMA20-16.21% SMA50-9.80% SMA200-18.57% Trades Volume596,002 Change1.25%
Date Action Analyst Rating Change Price Target Change
Jan-31-23Initiated Jefferies Buy $8
Jan-27-23Initiated Stifel Buy $9
May-23-22Resumed H.C. Wainwright Buy $12
Mar-15-22Initiated Ladenburg Thalmann Buy $7
Jan-19-22Initiated B. Riley Securities Buy $10
Dec-22-21Initiated Raymond James Outperform $5
Dec-20-21Initiated SVB Leerink Outperform $12
Dec-15-21Initiated Wedbush Outperform $8
Apr-12-24 08:00AM
Apr-10-24 08:00AM
Apr-09-24 12:00PM
Mar-21-24 10:54PM
09:00AM
08:00AM Loading…
Feb-29-24 08:00AM
Feb-28-24 08:00AM
Feb-08-24 12:00PM
Jan-05-24 08:00AM
Nov-09-23 08:17AM
07:30AM
Nov-07-23 08:00AM
Aug-30-23 08:00AM
Aug-03-23 08:00AM
Jun-22-23 04:05PM
10:06AM Loading…
Jun-01-23 10:06AM
May-04-23 08:30AM
Apr-26-23 08:30AM
Apr-19-23 08:30AM
Mar-28-23 08:30AM
Mar-15-23 08:30AM
Feb-16-23 07:28AM
Feb-02-23 08:30AM
Jan-25-23 06:39AM
Jan-19-23 05:00PM
Jan-06-23 08:30AM
Dec-15-22 08:30AM
Dec-01-22 08:30AM
Nov-22-22 08:00AM
Nov-09-22 09:00AM
08:00AM Loading…
Nov-08-22 08:00AM
Nov-02-22 09:06AM
Oct-11-22 08:00AM
Sep-09-22 08:00AM
Aug-02-22 08:00AM
Aug-01-22 08:00AM
Jul-18-22 07:05AM
May-31-22 08:00AM
May-23-22 08:00AM
May-20-22 06:28AM
May-16-22 08:00AM
May-09-22 01:59PM
08:00AM
May-05-22 08:00AM
May-04-22 07:00AM
May-03-22 04:01PM
Apr-26-22 08:00AM
Apr-08-22 01:01PM
Mar-30-22 08:00AM
Mar-21-22 08:00AM
Feb-07-22 05:38PM
Jan-28-22 05:38PM
Jan-20-22 08:30AM
Jan-07-22 09:00AM
Nov-22-21 10:00AM
Nov-12-21 08:30AM
Nov-03-21 08:04AM
Nov-01-21 11:13PM
04:30PM
04:03PM
Oct-08-21 12:07PM
Oct-01-21 07:00AM
Sep-20-21 08:35AM
Sep-10-21 08:35AM
Aug-13-21 07:00AM
May-13-21 02:02PM
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.